Given the lack of data on any Th17-related biomarkers in the CSF of any mice used in these studies, an outstanding question is whether an opportunity exists to further lower amyloidosis and astrocytosis by targeting IL-17 in both the periphery and CNS. Here, IL17A is linked to amyloidosis.